Single-arm, multicentre phase II trial of sintilimab plus platinum-based doublet chemotherapy followed by adaptive radiotherapy strategy for patients with unresectable stage III non-small-cell lung cancer in China: the ART-LUNG 01 study protocol. (PubMed, BMJ Open) - Sep 30, 2026 - P2 | "Individual participant data will be available on reasonable request after study completion, subject to institutional and ethical approvals. NCT07138755."
Clinical protocol • IO biomarker • Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor
|
|
Li Wu; Shuyun Ma; Xi Zhang; Xuewen Liu; Zewen Song
|